Literature DB >> 30442648

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.

Clémence Gorlier1, Ana-Maria Orbai2, Déborah Puyraimond-Zemmour1, Laura C Coates3, Uta Kiltz4, Ying-Ying Leung5, Penelope Palominos6, Juan D Cañete7, Rossana Scrivo8, Andra Balanescu9, Emmanuelle Dernis10, Sandra Tälli11, Adeline Ruyssen-Witrand12, Martin Soubrier13, Sibel Zehra Aydin14, Lihi Eder15, Inna Gaydukova16, Ennio Lubrano17, Umut Kalyoncu18, Pascal Richette19,20, M Elaine Husni21, Maarten de Wit22, Josef S Smolen23, Laure Gossec24,25.   

Abstract

BACKGROUND: The objective was to compare different definitions of remission and low disease activity (LDA) in patients with psoriatic arthritis (PsA), based on both patients' and physicians' perspectives.
METHODS: In ReFlap (Remission/Flare in PsA; NCT03119805), adults with physician-confirmed PsA and >2 years of disease duration in 14 countries were included. Remission was defined as very low disease activity (VLDA), Disease Activity index for PSoriatic Arthritis (DAPSA) ≤4, and physician-perceived and patient-perceived remission (specific question yes/no), and LDA as minimal disease activity (MDA), DAPSA <14, and physician-perceived and patient-perceived LDA. Frequencies of these definitions, their agreement (prevalence-adjusted kappa), and sensitivity and specificity versus patient-defined status were assessed cross-sectionally.
RESULTS: Of 410 patients, the mean age (SD) was 53.9 (12.5) years, 50.7% were male, disease duration was 11.2 (8.2) years, 56.8% were on biologics, and remission/LDA was frequently attained: respectively, for remission from 12.4% (VLDA) to 36.1% (physician-perceived remission), and for LDA from 25.4% (MDA) to 43.9% (patient-perceived LDA). Thus, patient-perceived remission/LDA was frequent (65.4%). Agreement between patient-perceived remission/LDA and composite scores was moderate to good (kappa range, 0.12-0.65). When patient-perceived remission or LDA status is used as reference, DAPSA-defined remission/LDA and VLDA/MDA had a sensitivity of 73.1% and 51.5%, respectively, and a specificity of 76.8% and 88.0%, respectively. Physician-perceived remission/LDA using a single question was frequent (67.6%) but performed poorly against other definitions.
CONCLUSION: In this unselected population, remission/LDA was frequently attained. VLDA/MDA was a more stringent definition than DAPSA-based remission/LDA. DAPSA-based remission/LDA performed better than VLDA/MDA to detect patient-defined remission or remission/LDA. Further studies of long-term outcomes are needed. © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  disease activity; patient perspective; psoriatic arthritis

Mesh:

Substances:

Year:  2018        PMID: 30442648     DOI: 10.1136/annrheumdis-2018-214140

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

Review 1.  PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Authors:  Ana-Maria Orbai; Richard Holland; Ying Ying Leung; William Tillett; Niti Goel; Robin Christensen; Neil McHugh; Laure Gossec; Maarten de Wit; Pil Højgaard; Laura C Coates; Philip J Mease; Julie Birt; Lara Fallon; Oliver FitzGerald; Alexis Ogdie; Beverly Shea; Vibeke Strand; Kristina Callis Duffin; Peter Tugwell; Dorcas Beaton; Dafna D Gladman
Journal:  J Rheumatol       Date:  2018-12-15       Impact factor: 4.666

2.  Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries.

Authors:  Ana-Maria Orbai; Jamie Perin; Clémence Gorlier; Laura C Coates; Uta Kiltz; Ying Ying Leung; Penelope E Palominos; Juan D Cañete; Rossana Scrivo; Andra Balanescu; Emmanuelle Dernis; Sandra Tälli; Adeline Ruyssen-Witrand; Martin Soubrier; Sibel Aydin; Lihi Eder; Inna Gaydukova; Ennio Lubrano; Umut Kalyoncu; Pascal Richette; M Elaine Husni; Josef S Smolen; Maarten de Wit; Laure Gossec
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-12       Impact factor: 4.794

3.  Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.

Authors:  Laura C Coates; Farrouq Mahmood; Jane Freeston; Paul Emery; Philip G Conaghan; Philip S Helliwell
Journal:  Rheumatology (Oxford)       Date:  2020-04-01       Impact factor: 7.580

4.  Expression of VEGFA-mRNA in classical and MSX2-mRNA in non-classical monocytes in patients with spondyloarthritis is associated with peripheral arthritis.

Authors:  Małgorzata Stec; Michał Seweryn; Mariusz Korkosz; Zofia Guła; Rafał Szatanek; Kazimierz Węglarczyk; Magdalena Rutkowska-Zapała; Marzena Lenart; Marcin Czepiel; Jarosław Czyż; Jarosław Baran; Anna Gruca; Kamila Wojnar-Lasoń; Paweł Wołkow; Maciej Siedlar
Journal:  Sci Rep       Date:  2021-05-06       Impact factor: 4.379

Review 5.  Treat-to-target in PsA: methods and necessity.

Authors:  Emma Dures; Sasha Shepperd; Sandeep Mukherjee; Jo Robson; Ivo Vlaev; Nicola Walsh; Laura C Coates
Journal:  RMD Open       Date:  2020-02

6.  Comparison of disease activity measures in early psoriatic arthritis in usual care.

Authors:  Kim Wervers; Jolanda J Luime; Ilja Tchetverikov; Andreas H Gerards; Marc R Kok; Cathelijne W Y Appels; Wiebo L van der Graaff; Johannes H L M van Groenendael; Lindy-Anne Korswagen; Josien J Veris-van Dieren; Johanna M W Hazes; Marijn Vis
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

7.  Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis.

Authors:  Ying Ying Leung; Ana-Maria Orbai; Maarten de Wit; Andra Balanescu; Emmanuelle Dernis; Martin Soubrier; Lihi Eder; Josef S Smolen; Laura C Coates; Laure Gossec
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-03-13       Impact factor: 4.794

8.  Measurement of Minimal Disease Activity in Psoriatic Arthritis Using the Patient-Reported Outcomes Measurement Information System-Physical Function or the Health Assessment Questionnaire Disability Index.

Authors:  Erin Chew; Jamie Perin; Thomas Grader-Beck; Ana-Maria Orbai
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-12-17       Impact factor: 4.794

9.  Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices.

Authors:  Ennio Lubrano; Silvia Scriffignano; Ana Belen Azuaga; Julio Ramirez; Juan D Cañete; Fabio Massimo Perrotta
Journal:  RMD Open       Date:  2020-03

10.  Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study.

Authors:  Ruben Queiro; Juan D Cañete; María Montoro; Susana Gómez; Ana Cábez
Journal:  Arthritis Res Ther       Date:  2020-04-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.